150 related articles for article (PubMed ID: 17989329)
1. Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography.
Ghersin E; Keidar Z; Eldad DJ; Bar-Shalom R; Fischer D; Halachmi S
Br J Radiol; 2007 Nov; 80(959):e283-6. PubMed ID: 17989329
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
3. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
5. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
6. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
8. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
9. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
10. Diffuse skeletal muscle F-18 fluorodeoxyglucose uptake in advanced primary muscle non-Hodgkin's lymphoma.
Broski SM; Bou-Assaly W; Gross MD; Fig LM
Clin Nucl Med; 2009 Apr; 34(4):251-3. PubMed ID: 19300063
[TBL] [Abstract][Full Text] [Related]
11. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
Bodet-Milin C; Kraeber-Bodéré F; Moreau P; Campion L; Dupas B; Le Gouill S
Haematologica; 2008 Mar; 93(3):471-2. PubMed ID: 18310543
[TBL] [Abstract][Full Text] [Related]
12. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT.
Papajik T; Myslivecek M; Skopalova M; Malan A; Buriankova E; Koza V; Hnatkova M; Trneny M; Sedova Z; Kubova Z; Koranda P; Flodr P; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2011; 58(4):291-7. PubMed ID: 21524147
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
16. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
18. Secondary neurolymphomatosis of spinal nerve roots detected by ¹⁸F-FDG PET/CT: a case report and differential diagnosis of the case.
Wang Y; Wang J; Jiang C; Peng Q; Wu M; Ma X
Hell J Nucl Med; 2015; 18(3):261-3. PubMed ID: 26574697
[TBL] [Abstract][Full Text] [Related]
19. Imaging by ¹⁸F-FDG PET/CT of diffuse large B-cell lymphoma with cellulitis.
Zhang Y; Li B; Cai L; Shi H; Hou J
Hell J Nucl Med; 2015; 18(3):271-2. PubMed ID: 26574700
[TBL] [Abstract][Full Text] [Related]
20. Post-therapy lesions in patients with non-Hodgkin's lymphoma characterized by 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm.
Radhakrishnan RK; Mittal BR; Basher RK; Prakash G; Malhotra P; Kalra N; Das A
Nucl Med Commun; 2018 Jan; 39(1):74-82. PubMed ID: 29189443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
